



Department of Health Care Finance



PHARMACY & THERAPEUTICS
COMMITTEE MEETING

December 3rd, 2020

Time: 2:30 PM – 5:30 PM

Online Only

*Please register at:

https://magellanhealth.zoom.us/webinar/register/WN_XV7PVkorR8G0ZIC18zGpiw

- | | |
|--------------------------------------|---|
| 1) Call to Order | Charlene Fairfax, RPh |
| 2) Minutes of Previous Meeting | Charlene Fairfax, RPh |
| 3) Comments from Interested Parties* | Gidey Amare, RPh, MS |
| 4) Clinical Drug Class Reviews | Zakia Al-Amin, PharmD, BCACP RPh
Ronald E. Kavanagh, BSP Pharm, PharmD, PhD, RPh |

Angiotensin Modulator Combinations	Hemophilia Agents (<i>Tentative</i>)
Angiotensin Modulators	Hepatitis B Agents
Antianginal Agents (Ranexa)	Hepatitis C Agents
Antibiotics, Topical	HIV and AIDS Treatments
Anticoagulants	Immunomodulators, Atopic Dermatitis
Antihypertensives, Sympatholytics	Immunomodulators, Topical
Antipsoriatics, Oral	Lipotropics, Others
Antipsoriatics, Topical	Lipotropics, Statins
Antiviral Agents, Oral (HSV & Influenza)	Methotrexate
Antiviral Agents, Topical	Platelet Aggregation Inhibitors
Beta-Blockers	Rosacea Agents, Topical
Calcium Channel Blockers	Sickle Cell Anemia Agents (<i>Tentative</i>)

- | | |
|--|--|
| 5) Executive Session (Committee Only) ** | Charlene Fairfax, RPh
MMA Representatives |
| 6) Final Recommendations of Preferred Drugs*** | MMA Representatives |
| 7) Announcement of Next Scheduled P&T Committee Meeting
Thursday March 4 th , 2021 | Charlene Fairfax, RPh |
| 8) Final Comments and Adjournment | Charlene Fairfax, RPh |

*Individuals wishing to make oral presentations to the Committee will be limited to three (3) minutes only

**Closed Session

***Open Session